FR06C0009I2 - - Google Patents
Info
- Publication number
- FR06C0009I2 FR06C0009I2 FR06C0009C FR06C0009C FR06C0009I2 FR 06C0009 I2 FR06C0009 I2 FR 06C0009I2 FR 06C0009 C FR06C0009 C FR 06C0009C FR 06C0009 C FR06C0009 C FR 06C0009C FR 06C0009 I2 FR06C0009 I2 FR 06C0009I2
- Authority
- FR
- France
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Dental Preparations (AREA)
- Lubricants (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Thermal Transfer Or Thermal Recording In General (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17108393A | 1993-12-21 | 1993-12-21 | |
| PCT/US1994/014236 WO1995017407A1 (en) | 1993-12-21 | 1994-12-20 | Tetrahydrofuran antifungals |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FR06C0009I1 FR06C0009I1 (OSRAM) | 2006-05-19 |
| FR06C0009I2 true FR06C0009I2 (OSRAM) | 2006-12-29 |
Family
ID=22622452
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR06C0009C Active FR06C0009I2 (OSRAM) | 1993-12-21 | 2006-03-13 |
Country Status (28)
| Country | Link |
|---|---|
| EP (1) | EP0736030B1 (OSRAM) |
| JP (1) | JP2834889B2 (OSRAM) |
| KR (1) | KR0179990B1 (OSRAM) |
| CN (1) | CN1064685C (OSRAM) |
| AT (1) | ATE204875T1 (OSRAM) |
| AU (1) | AU681753B2 (OSRAM) |
| BR (1) | BR1100154B1 (OSRAM) |
| CA (1) | CA2179396C (OSRAM) |
| CO (1) | CO4520281A1 (OSRAM) |
| CZ (1) | CZ294823B6 (OSRAM) |
| DE (2) | DE69428125T2 (OSRAM) |
| DK (1) | DK0736030T3 (OSRAM) |
| ES (1) | ES2159623T3 (OSRAM) |
| FI (1) | FI118470B (OSRAM) |
| FR (1) | FR06C0009I2 (OSRAM) |
| HU (1) | HU225062B1 (OSRAM) |
| IL (1) | IL112081A (OSRAM) |
| LU (1) | LU91216I2 (OSRAM) |
| MY (1) | MY130217A (OSRAM) |
| NL (1) | NL300219I2 (OSRAM) |
| NO (2) | NO316173B1 (OSRAM) |
| NZ (1) | NZ278713A (OSRAM) |
| PL (1) | PL181193B1 (OSRAM) |
| PT (1) | PT736030E (OSRAM) |
| SK (1) | SK283035B6 (OSRAM) |
| TW (1) | TW377349B (OSRAM) |
| WO (1) | WO1995017407A1 (OSRAM) |
| ZA (1) | ZA9410142B (OSRAM) |
Families Citing this family (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995019983A1 (en) * | 1994-01-24 | 1995-07-27 | Janssen Pharmaceutica N.V. | Watersoluble azole antifungals |
| ATE240319T1 (de) * | 1995-06-02 | 2003-05-15 | Schering Corp | Antifungale tetrahydrofurane |
| US5698557A (en) * | 1995-06-19 | 1997-12-16 | Schering Corporation | Hydroxy-substituted antifungals |
| EP0837859B1 (en) * | 1995-06-19 | 2003-08-13 | Schering Corporation | Tetrahydrofuran antifungals |
| IL125007A (en) * | 1995-12-20 | 2001-09-13 | Schering Corp | Process for the preparation of hydrazides |
| US5834472A (en) * | 1996-05-24 | 1998-11-10 | Schering Corporation | Antifungal composition with enhanced bioavailability |
| RU2207119C2 (ru) | 1996-05-24 | 2003-06-27 | Шеринг Корпорейшн | Противогрибковый состав с повышенной биодоступностью |
| ATE273002T1 (de) * | 1996-06-28 | 2004-08-15 | Schering Corp | Feste lösung eines fungizids mit erhöhter bioverfügbarkeit |
| US5972381A (en) * | 1996-06-28 | 1999-10-26 | Schering Corporation | Solid solution of an antifungal agent with enhanced bioavailability |
| US5846971A (en) * | 1996-06-28 | 1998-12-08 | Schering Corporation | Oral antifungal composition |
| CA2258683C (en) * | 1996-06-28 | 2007-07-31 | Schering Corporation | Oral composition comprising a triazole antifungal compound |
| AU5178998A (en) * | 1996-11-12 | 1998-06-03 | Sepracor, Inc. | 2(r),4(s),(r),(s)- and 2(s),4(r),(r),(s)-hydroxyitraconazole- and hydroxysaperconazole derivatives |
| AU5251398A (en) * | 1996-11-12 | 1998-06-03 | Sepracor, Inc. | (2r,4s,r,r-) and (2s,4r,r,r-)hydroxyitraconazole |
| JP2001504465A (ja) | 1996-11-12 | 2001-04-03 | セプラコール，インク． | ２ｒ，４ｓ，ｓ，ｓ―および２ｓ，４ｒ，ｓ，ｓ―ヒドロキシイトラコナゾール |
| JP2001504464A (ja) * | 1996-11-12 | 2001-04-03 | セプラコール，インク． | ２ｒ，４ｓ，ｓ，ｒ―および２ｓ，４ｒ，ｓ，ｒ―ヒドロキシイトラコナゾール |
| US5684197A (en) * | 1996-12-12 | 1997-11-04 | Schering Corporation | Process for preparation of hydrazides |
| ATE270290T1 (de) * | 1997-02-11 | 2004-07-15 | Janssen Pharmaceutica Nv | Azole enthaltende antifungale aminosäure-ester |
| EP1027349B1 (en) * | 1997-09-25 | 2005-01-05 | Schering Corporation | Tetrahydrofuran phosphate- and hydroxy esters, as prodrugs for the corresponding antifungal agent |
| US6043245A (en) * | 1997-09-25 | 2000-03-28 | Schering Corporation | Tetrahydrofuran antifungal phosphate |
| AR015947A1 (es) * | 1997-10-07 | 2001-05-30 | Schering Corp | Una forma 1 polimorfica (-)-4-[4-[4-[4-[[(2r-cis]-5-(2,4-difluorfenil)tetrahidro-5-(1h-1,2,4-triazol-1-ilmetil)furan-3-il]-metoxi]fenil]-1-piperazinil]fenil-2,4-dihidro-2-[(s)-1-etil-2-(s)-hidroxipropil]-3h-1,2,4-triazol-3-ona, composicion farmaceutica que la contiene y su uso para preparar un medic |
| AU9592998A (en) * | 1997-10-07 | 1999-04-27 | Schering Corporation | Crystalline antifungal glycine ester polymorph |
| US6713481B1 (en) * | 1997-10-17 | 2004-03-30 | David R. Andrews | Crystalline antifungal polymorph |
| US5883097A (en) * | 1998-04-16 | 1999-03-16 | Schering Corporation | Soluble azole antifungal salt |
| EP0957101A1 (en) * | 1998-05-14 | 1999-11-17 | Janssen Pharmaceutica N.V. | Water soluble azoles as broad-spectrum antifungals |
| US6147077A (en) * | 1999-04-29 | 2000-11-14 | Sepracor Inc. | 2R,4S-hydroxyitraconazole isomers |
| US6583136B1 (en) * | 1999-05-04 | 2003-06-24 | Janssen Pharmacuetica N.V. | Antifungal ethers |
| US6362172B2 (en) | 2000-01-20 | 2002-03-26 | Bristol-Myers Squibb Company | Water soluble prodrugs of azole compounds |
| US6448401B1 (en) | 2000-11-20 | 2002-09-10 | Bristol-Myers Squibb Company | Process for water soluble azole compounds |
| AU2002257104B2 (en) * | 2001-04-03 | 2006-02-09 | Merck Sharp & Dohme Corp. | Antifungal composition with enhanced bioavailability |
| US7446107B2 (en) | 2002-02-15 | 2008-11-04 | Transform Pharmaceuticals, Inc. | Crystalline forms of conazoles and methods of making and using the same |
| US7078526B2 (en) | 2002-05-31 | 2006-07-18 | Transform Pharmaceuticals, Inc. | CIS-itraconazole crystalline forms and related processes, pharmaceutical compositions and methods |
| US7927613B2 (en) | 2002-02-15 | 2011-04-19 | University Of South Florida | Pharmaceutical co-crystal compositions |
| US7790905B2 (en) | 2002-02-15 | 2010-09-07 | Mcneil-Ppc, Inc. | Pharmaceutical propylene glycol solvate compositions |
| CA2477088A1 (en) | 2002-02-22 | 2003-10-02 | New River Pharmaceuticals Inc. | Active agent delivery systems and methods for protecting and administering active agents |
| AU2003213719A1 (en) | 2002-03-01 | 2003-09-16 | Regents Of The University Of Michigan | Multiple-component solid phases containing at least one active pharmaceutical ingredient |
| MXPA05000232A (es) | 2002-06-21 | 2005-06-17 | Transform Pharmaceuticals Inc | Composiciones farmaceuticas con disolucion mejorada. |
| US8183290B2 (en) | 2002-12-30 | 2012-05-22 | Mcneil-Ppc, Inc. | Pharmaceutically acceptable propylene glycol solvate of naproxen |
| ITMI20032020A1 (it) | 2003-10-17 | 2005-04-18 | Italfarmaco Spa | Nuovi agenti antifungini azolici con diminuita interazione con i citocromi metabolici |
| BRPI0514098B1 (pt) * | 2004-08-13 | 2021-01-19 | Intervet International B. V. | composição farmacêutica tópica para o tratamento de uma infecção ótica |
| JO2691B1 (en) * | 2005-05-03 | 2013-03-03 | ايساي آر آند دي مانجمنت كو.، ليمتد | Monolysine salts for azole compounds |
| EP2130540A1 (en) * | 2008-06-02 | 2009-12-09 | Sandoz AG | Pharmaceutical compositions containing a crystalline form of posaconazole |
| EP2141159A1 (en) | 2008-07-03 | 2010-01-06 | Sandoz AG | A Crystalline form of posaconazole |
| US20120101277A1 (en) | 2009-07-09 | 2012-04-26 | Sandoz Ag | Crystalline form of posaconazole |
| WO2011158248A2 (en) * | 2010-05-12 | 2011-12-22 | Glenmark Generics Limited | Process for preparation of posaconazole and crystalline polymorphic form v of posaconazole |
| BR112012029226A2 (pt) * | 2010-05-19 | 2015-10-20 | Sandoz Ag | processo para a preparação de um composto quiral, composto quiral cristalino, sal de hcl do composto quiral cristalino, composto quiral e uso do composto |
| CN102892763B (zh) * | 2010-05-19 | 2016-03-09 | 桑多斯股份公司 | 泊沙康唑及泊沙康唑中间体的纯化 |
| BR112012029225B1 (pt) * | 2010-05-19 | 2020-10-27 | Sandoz Ag | processo para a preparação de um composto quiral, composto quiral e uso de um composto quiral |
| RU2585760C2 (ru) * | 2010-05-19 | 2016-06-10 | Сандоз Аг | Способ получения хиральных триазолонов |
| EP3960185A1 (en) | 2010-06-29 | 2022-03-02 | Merck Sharp & Dohme Corp. | Posaconazole intravenous solution formulations stabilized by substituted beta-cyclodextrin |
| WO2012172015A1 (en) | 2011-06-16 | 2012-12-20 | Sandoz Ag | Process for the preparation of a chiral compound |
| EP2789610A1 (en) | 2013-04-10 | 2014-10-15 | Sandoz Ag | Purification of Posaconazole Intermediates |
| WO2015011224A1 (en) * | 2013-07-25 | 2015-01-29 | Sandoz Ag | Improved process for the preparation of crystalline form iv of posaconazole |
| ITMI20132114A1 (it) | 2013-12-18 | 2015-06-19 | Djada Pharmaceutical Sa | Una forma cristallina di posaconazolo |
| CN105287403A (zh) * | 2014-08-02 | 2016-02-03 | 陕西合成药业股份有限公司 | 一种泊沙康唑前体药物的冻干组合物及其制备方法和用途 |
| CN104370894A (zh) * | 2014-10-21 | 2015-02-25 | 江苏恒盛药业有限公司 | 无定型泊沙康唑的制备工艺 |
| JP6669751B2 (ja) | 2014-12-05 | 2020-03-18 | プルモシデ リミテド | 抗真菌化合物 |
| ES2790723T3 (es) | 2015-05-21 | 2020-10-29 | Pulmocide Ltd | Antifúngico 4-(4-(4-(((3R,5R)-5-((1H-1,2,4-triazol-1-il)metil)-5-(2,4-difluorofenil)tetrahidrofurano-3-il)metoxi)-3-metilfenil)piperazina-1-il)-N -(2-hidroxiciclohexil)benzamida, o una sal farmacéuticamente aceptable del mismo |
| CN106317032A (zh) * | 2015-06-15 | 2017-01-11 | 重庆圣华曦药业股份有限公司 | 一种制备高纯度的泊沙康唑的方法 |
| CN106432338A (zh) * | 2015-08-08 | 2017-02-22 | 陕西合成药业股份有限公司 | 泊沙康唑衍生物、合成和在长效制剂中的用途 |
| ES2946734T3 (es) * | 2015-09-23 | 2023-07-25 | Biocon Ltd | Formas cristalinas del intermedio de posaconazol y procedimiento para la preparación de posaconazol amorfo |
| CN105606736A (zh) * | 2016-01-27 | 2016-05-25 | 重庆华邦制药有限公司 | 分离测定泊沙康唑中间体z1及其有关物质的方法 |
| SI3424911T1 (sl) * | 2016-03-04 | 2021-11-30 | Zhejiang Ausun Pharmaceutical Co., Ltd., | Posakonazol, sestavek, intermediat, postopek priprave le-tega in uporabe le-tega |
| CN105949278B (zh) * | 2016-03-30 | 2019-12-06 | 南京曼杰生物科技有限公司 | 一种取代的四氢呋喃水溶性衍生物及其应用 |
| WO2017032908A1 (en) | 2016-07-08 | 2017-03-02 | Synthon B.V. | Pharmaceutical composition comprising amorphous posaconazole |
| EP3558304A2 (en) | 2016-12-23 | 2019-10-30 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Inhibitors of cytochrome p450 family 7 subfamily b member 1 (cyp7b1) for use in treating diseases |
| TR201620462A2 (tr) | 2016-12-31 | 2018-07-23 | Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi | POSAKONAZOL İÇEREN FARMASÖTİK BİLEŞİMLER ve ÜRETİM YÖNTEMİ |
| CN106967054A (zh) * | 2017-03-30 | 2017-07-21 | 成都绿林科技有限公司 | 一种泊沙康唑的制备方法 |
| CN106883221A (zh) * | 2017-04-17 | 2017-06-23 | 兰州大学 | 一种无定形泊沙康唑及其制备方法 |
| CN108341754A (zh) * | 2018-03-12 | 2018-07-31 | 扬子江药业集团有限公司 | 泊沙康唑杂质及其制备方法和用途 |
| CN110938093B (zh) * | 2018-09-21 | 2022-08-19 | 华创合成制药股份有限公司 | 一种泊沙康唑磷酸酯单胆碱盐及其制备方法和用途 |
| CN112778369B (zh) * | 2019-11-05 | 2024-01-26 | 华创合成制药股份有限公司 | 一种三唑类衍生物及其制备方法和用途 |
| GB201917867D0 (en) | 2019-12-06 | 2020-01-22 | Pulmocide Ltd | Polymorphs |
| CN113666915B (zh) * | 2021-08-27 | 2022-08-16 | 江苏海洋大学 | 一种泊沙康唑中间体的制备方法 |
| CN114315811B (zh) * | 2021-11-19 | 2024-04-30 | 江苏恒盛药业有限公司 | 一种三氮唑类似物化合物及其制备方法和应用 |
| CN120794964A (zh) * | 2025-07-03 | 2025-10-17 | 广州绿十字制药股份有限公司 | 泊沙康唑脂肪酸酯、泊沙康唑脂肪酸酯脂肪乳及其制备方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4218458A (en) * | 1978-06-23 | 1980-08-19 | Janssen Pharmaceutica, N.V. | Heterocyclic derivatives of (4-aryloxy-methyl-1,3-dioxolan-2-yl)methyl-1H-imidazoles and 1H-1,2,4-triazoles |
| CA1292472C (en) * | 1985-12-03 | 1991-11-26 | Alfonsus Guilielmus Knaeps | Derivatives of ¬¬4-¬4-(4-phenyl-1-piperazinyl)- phenoxymethyl|-1,3-dioxolan-2-yl|methyl|-1h-imidazoles and 1h-1,2,4-triazoles |
| DE3852477T2 (de) * | 1987-11-20 | 1995-05-04 | Schering Corp | Tri- und tetrasubstituierte Oxetane und Tetrahydrofurane und deren Zwischenprodukte. |
| US5039676A (en) * | 1990-05-11 | 1991-08-13 | Schering Corporation | Tri- and tetra-substituted-oxetanes and tetrahydrofurans and intermediates thereof |
| IL103558A0 (en) * | 1991-10-30 | 1993-03-15 | Schering Corp | Tri-substituted tetrahydrofuran antifungals |
-
1994
- 1994-12-20 TW TW083111949A patent/TW377349B/zh not_active IP Right Cessation
- 1994-12-20 CO CO94057442A patent/CO4520281A1/es unknown
- 1994-12-20 DE DE69428125T patent/DE69428125T2/de not_active Expired - Lifetime
- 1994-12-20 CN CN94195025A patent/CN1064685C/zh not_active Expired - Lifetime
- 1994-12-20 DK DK95906620T patent/DK0736030T3/da active
- 1994-12-20 ZA ZA9410142A patent/ZA9410142B/xx unknown
- 1994-12-20 EP EP95906620A patent/EP0736030B1/en not_active Expired - Lifetime
- 1994-12-20 AT AT95906620T patent/ATE204875T1/de active
- 1994-12-20 ES ES95906620T patent/ES2159623T3/es not_active Expired - Lifetime
- 1994-12-20 CZ CZ19961805A patent/CZ294823B6/cs not_active IP Right Cessation
- 1994-12-20 IL IL11208194A patent/IL112081A/xx active Protection Beyond IP Right Term
- 1994-12-20 MY MYPI94003426A patent/MY130217A/en unknown
- 1994-12-20 CA CA002179396A patent/CA2179396C/en not_active Expired - Lifetime
- 1994-12-20 JP JP7517469A patent/JP2834889B2/ja not_active Expired - Lifetime
- 1994-12-20 PT PT95906620T patent/PT736030E/pt unknown
- 1994-12-20 NZ NZ278713A patent/NZ278713A/en not_active IP Right Cessation
- 1994-12-20 DE DE1994628125 patent/DE122006000004I2/de active Active
- 1994-12-20 WO PCT/US1994/014236 patent/WO1995017407A1/en not_active Ceased
- 1994-12-20 PL PL94315169A patent/PL181193B1/pl unknown
- 1994-12-20 SK SK826-96A patent/SK283035B6/sk not_active IP Right Cessation
- 1994-12-20 HU HU9601709A patent/HU225062B1/hu active Protection Beyond IP Right Term
- 1994-12-20 AU AU15127/95A patent/AU681753B2/en not_active Expired
-
1996
- 1996-06-20 NO NO19962616A patent/NO316173B1/no not_active IP Right Cessation
- 1996-06-20 FI FI962577A patent/FI118470B/fi not_active IP Right Cessation
- 1996-06-21 KR KR1019960703319A patent/KR0179990B1/ko not_active Expired - Lifetime
-
1997
- 1997-03-06 BR BR1100154A patent/BR1100154B1/pt unknown
-
2006
- 2006-01-27 LU LU91216C patent/LU91216I2/en unknown
- 2006-02-01 NL NL300219C patent/NL300219I2/nl unknown
- 2006-02-10 NO NO2006002C patent/NO2006002I2/no unknown
- 2006-03-13 FR FR06C0009C patent/FR06C0009I2/fr active Active